Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use

Cancer

Volumn 116, Issue 9, 2010, Pages 2115-2125

  Rozen, Paul ^a,b   Comaneshter, Doron ^c   Levi, Zohar ^a   Hazazi, Rachel ^a   Vilkin, Alex ^a   Maoz, Eran ^d   Birkenfeld, Shlomo ^d   Niv, Yaron ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d CLALIT HEALTH SERVICES   (Israel)

Author keywords

Adenoma; Colorectal cancer; Fecal occult blood; Immunochemical fecal occult blood test; Predictive values; Sensitivity; Specificity

Indexed keywords

HEMOGLOBIN;

ADENOMATOUS POLYP; ADULT; AGED; ARTICLE; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; FEMALE; FOLLOW UP; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADENOMATOUS POLYPS; COLONIC POLYPS; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; HEMOGLOBINS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OCCULT BLOOD; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 77951494866     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25012     Document Type: Article

References (29)

1. Rozen P, Levi Z, Hazazi R, et al. Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms. Aliment Pharmacol Ther. 2009;29:450-457.
2. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2009;59:27-41.
3. Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin. 2006;56:143-159. (Pubitemid 43847925)
4. Nakama H, Zhang B, Fattah ASMA. A cost-effective analysis of the optimum number of stool specimens collected for immunochemical occult blood screening for colorectal cancer. Eur J Cancer. 2000;36:647-650. (Pubitemid 30156851)
5. Nakama H, Zhang B, Zhang Y. Evaluation of the optimum cut-off point in immunochemical occult blood testing in screening for colorectal cancer. Eur J Cancer. 2001;37: 398-401. (Pubitemid 32182330)
6. Wong WM, Lam SK, Cheung KL, et al. Evaluation of an automated immunochemical faecal occult blood test for colorectal neoplasia detection in a Chinese population. Cancer. 2003;97:2420-2424. (Pubitemid 36542480)
7. Morikawa T, Kato J, Yamaji Y, et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology. 2005;129:422-428. (Pubitemid 41096630)
8. Fenocchi E, Martinez L, Tolve J, et al. Screening for colorectal cancer in Uruguay with an immunochemical faecal occult blood test. Eur J Cancer Prev. 2006;15:384-390. (Pubitemid 44252909)
9. Smith A, Young GP, Cole SR, et al. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer. 2006;107:2152-2159. (Pubitemid 44665648)
10. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 2007;99:1462-1470.
11. Chen L-S, Liao C-S, Chang S-H, Lai H-C, Chen HH. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16). J Med Screen. 2007;14:191-199.
12. Castiglione G, Visioli CB, Ciatto S, et al. Sensitivity of latex agglutination faecal occult blood test in the Florence district population-based colorectal cancer screening programme. Br J Cancer. 2007;96:1750-1754. (Pubitemid 46847191)
13. Guittet L, Bouvier VM, Marriote N, et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut. 2007;56:210-214. (Pubitemid 46246209)
14. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008;135:82-90.
15. Grazzini G, Visioli CB, Zorzi M, et al. Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? Br J Cancer. 2009;100:259-265.
16. Leiberman DA, Holub J, Eisen G, et al. Utilization of colonoscopy in the United States: results from a national consortium. Gastrointest Endosc. 2005;62:875-883. (Pubitemid 41654422)
17. Rozen P, Waked A, Vilkin A, et al. Evaluation of a desk top instrument for the automated development and immunochemical quantification of fecal occult blood. Med Sci Monit. 2006;12:MT27-MT32. (Pubitemid 43854430)
18. Vilkin A, Rozen P, Levi Z, et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol. 2005;100:2519-2526. (Pubitemid 43919686)
19. Rozen P, Levi Z, Hazazi R, et al. Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed. Aliment Pharmacol Ther. 2009;29:906-917.
20. Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood screening test for colorectal neoplasia. Ann Intern Med. 2007;146:244-255. (Pubitemid 351650610)
21. Levi Z, Rozen P, Hazazi R, et al. Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants. Am J Gastroenterol. 2009;104:933-938.
22. Hol L, Wilschut JA, van Ballegooijen M, et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer. 2009;100:1103-1110.
23. Sawhney MS, Farrar WD, Gudiseva S, et al. Microsatellite instability in interval cancers. Gastroenterology. 2006;131: 1700-1705.
24. Bampton PA, Sandford JJ, Cole SR, et al. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology. Gut. 2005;54:803-806.
25. Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology. 1997;112:24-28.
26. Robertson DJ, Greenberg ER, Beach M, et al. Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology. 2005;129:34-41. (Pubitemid 41002040)
27. Pabby A, Schoen RE, Weissfeld JL, et al. Analysis of colorectal cancer occurrence during surveillance colonoscopy in the dietary Polyp Prevention Trial. Gastrointest Endosc. 2005;61:385-391. (Pubitemid 40349030)
28. Lieberman DA, Holub J, Eisen G, et al. Prevalence of polyps greater than 9 mm in a consortium of diverse clinical practice settings in the United States. Clin Gastroenterol Hepatol. 2005;3:798-805. (Pubitemid 41116733)
29. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med. 2000;343:169-174.